Unprecedented overall survival in patients with 1L ESCC and PD-L1 scores ≥1%1
Key Efficacy Outcome: OS in PD-L1 ≥1%
16.8 months of median overall survival with etapidi+ chemotherapy vs 9.6 months with placebo + chemotherapy
Limitation: Efficacy analysis was not powered for statistical comparison and is descriptive only. No definitive conclusions can be drawn
Key Efficacy Outcome: OS in PD-L1 ≥1%
Overall survival sustained over 3 years3
21.3% of patients were alive at 3 years with etapidi + chemotherapy (95% CI: 16.2-26.9) vs 14.3% with placebo + chemotherapy (95% CI: 10.1-19.2)
Limitation: The 3-year OS analysis was exploratory in nature and was not powered to show statistical significance. Landmark OS rates were estimated using the Kaplan-Meier method. No definitive conclusions can be drawn.
Subgroup Analyses: OS in PD-L1 ≥1%
A consistent trend in overall survival favoring etapidi + chemotherapy across multiple key subgroups3
In patients with 1L, unresectable, locally advanced ESCC and PD-L1 scores ≥1% (n=63):
etapidi + chemotherapy reported 25.6 months mOS vs 11.5 months mOS with placebo + chemotherapy4
In patients with metastatic ESCC and PD-L1 scores ≥1% (n=418):
etapidi + chemotherapy reported 16.3 months mOS vs 9.4 months mOS with placebo + chemotherapy4
Limitation: Post-hoc subgroup analyses were not statistically powered and were descriptive only. No definitive conclusions can be drawn.
Explore ORR, mDoR, and mPFS in patients with 1L ESCC
To evaluate treatment response, durability of response, and disease control in patients with first-line (1L) ESCC.
1L, first line; CRF, case report form; CPS, combined positive score; ECOG, Eastern Cooperative Oncology Group; ESCC, esophageal squamous cell carcinoma; HR, hazard ratio; IRT, interactive response technology; mOS, median overall survival; ORR, overall response rate; OS, overall survival; PD-L1, programmed death ligand 1; PFS, progression-free survival; PS, performance status.
References: 1. etapidi. Prescribing Information. BeOne Medicines USA, Inc.; 2025. 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Esophageal and Esophagogastric Junction Cancers V.2.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed February 25, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
3. Xu J, Kato K, Hubner R, et al. Adv Ther. Published online March 13, 2025. doi:10.1007/s12325-025-03115-9 4. Yoon HH, Kim SS, Xu J, et al. Abstract and poster presented at: ASCO Gastrointestinal Cancers Symposium; January 8-10, 2026. San Francisco, CA. Abstract 381, poster D12.